Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWER.
| Autor: | Biller BMK; Neuroendocrine Unit-Bulfinch 457B, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA., Höybye C; Department of Endocrinology and Department of Molecular Medicine and Surgery, Karolinska University Hospital and Karolinska Institute, 171 76 Stockholm, Sweden., Ferran JM; Qualiance ApS, Oehlenschlægersgade 4, 2, 1663 Copenhagen V, Denmark., Kelepouris N; US Medical Affairs-Rare Endocrine Disorders, Novo Nordisk Inc, Plainsboro, NJ 08536, USA., Nedjatian N; Global Medical Affairs-Rare Endocrine Disorders, Novo Nordisk Health Care AG, 8050 Zurich, Switzerland., Olsen AH; Epidemiology, Novo Nordisk A/S, 2860 Søborg, Denmark., Weber MM; Unit of Endocrinology, Medical Department, University Hospital, Universitätsmedizin Mainz, der Johannes Gutenberg-Universität, Langenbeckstraße 1, 55131 Mainz, Germany., Gordon MB; Allegheny Neuroendocrinology Center, Division of Endocrinology, Allegheny General Hospital, Pittsburgh, PA 15212, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of the Endocrine Society [J Endocr Soc] 2023 Apr 26; Vol. 7 (6), pp. bvad054. Date of Electronic Publication: 2023 Apr 26 (Print Publication: 2023). |
| DOI: | 10.1210/jendso/bvad054 |
| Abstrakt: | Context: Effectiveness and safety data on GH replacement therapy (GHRT) in older adults with adult GH deficiency (AGHD) are limited. Objective: To compare GHRT safety and clinical outcomes in older (≥60 years and, for some outcomes, ≥75 years) and middle-aged (35-<60 years) patients with AGHD. Design/setting: Ten-year follow-up, real-world data from 2 large noninterventional studies-NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program-were analyzed. Patients: GH-naïve and non-naïve patients with AGHD. Intervention: Norditropin® (somatropin). Main Outcome Measures: Outcomes included GH exposure, IGF-I standard deviation scores (SDS), body mass index (BMI), glycated hemoglobin (HbA Results: The effectiveness analysis set comprised 545 middle-aged and 214 older patients (19 aged ≥75 years) from NordiNet® IOS. The full analysis set comprised 1696 middle-aged and 652 older patients (59 aged ≥75 years) from both studies. Mean GH doses were higher in middle-aged vs older patients. For both age groups and sexes, mean IGF-I SDS increased following GHRT, while BMI and HbA Conclusion: Clinical outcomes of GHRT in AGHD were similar in middle-aged and older patients, with no significantly increased risk of GHRT-related adverse reactions in older patients. (© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|